Abstract

Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable. However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities. In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.

Author affiliations

1. Henk M. W. Verheul is at the University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
2. Herbert M. Pinedo is at the VU Medical Center Amsterdam, De Boelelaan 1015, 1081 HV, Amsterdam, The Netherlands.

Correspondence to: Herbert M. Pinedo² Email: hm.pinedo@vumc.nl

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.